SARS-CoV-2

[Blood Cancer Journal] In lymphoma patients mean antibody levels and seroconversion rates were lower than in other hematologic malignancies patients, primarily because all nine patients who had received rituximab within six months before COVID-19 failed to produce anti-nucleocapsid and anti-spike-antibody.

[Science Advances] Scientists used ferrets and rhesus macaques challenged with SARS-CoV-2 to assess the potential for vaccine-enhanced disease in animals vaccinated with formaldehyde-inactivated SARS-CoV-2 formulated with Alhydrogel, compared to a negative control vaccine.

[Spikimm (BusinessWire, Inc.)] SpikImm reports that SPKM001, their high affinity human monoclonal antibody, potently neutralizes the original SARS-CoV-2 strain as well as its variants of concern, including the Alpha, Beta, Gamma, Delta and Delta Plus variants.

[Signal Transduction and Targeted Therapy] Investigators summarize the recent progress in MSC therapy for COVID-19 and highlight the challenges in the field.

[Cell] Researchers found that the emergence of these three “501Y lineages” coincided with a major global shift in the selective forces acting on various SARS-CoV-2 genes.

[Cell Discovery] A novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates.